prostate cancer

[Oncogene] Deregulation of CSN5, a putative androgen receptor (AR), could affect diverse cellular functions that contribute to tumor development. Inhibition of CSN5 repressed metabolic pathways, including oxidative phosphorylation and glycolysis in AR-negative prostate cancer cells.

[British Journal of Cancer] Investigators identified that PCK1 was a pivotal regulator in therapy-induced neuroendocrine differentiation of prostate cancer through a LIF/ZBTB46-driven glucose metabolism pathway.

[American Journal of Human Genetics] The authors assessed the utility of chromosome conformation capture coupled with immunoprecipitation (HiChIP) to identify target genes for prostate cancer genome-wide association studies risk loci.

[Molecular Cancer therapeutics] Androgen receptor has essential roles in the growth of prostate cancer and some breast cancers. A combination of EPI-7170 with palbociclib attenuated the in vivo growth of human castration-resistant prostate cancer xenografts that were resistant to antiandrogens.

[Cell Death Discovery] The authors revealed that high concentrations of the sympathetic neurotransmitter norepinephrine induced neuroendocrine differentiation-like changes in prostate cancer cells in vitro, evident by their characteristic cellular and molecular changes.

[Journal of Experimental & Clinical Cancer Research] The authors investigated whether transmembrane serine protease 4 (TMPRSS4) confered cancer stem–like properties to prostate cancer cells and characterized the underlying mechanisms.